Executive Summary
A surge of 5 new S-1 filings on March 20, 2026, highlights a robust IPO pipeline across crypto ETFs, biotech, consumer tech, quantum computing M&A, nuclear energy, and early-stage tech, with the 6th providing context on governance evolution. Positive sentiments dominate in biotech (Artelo) and quantum (IonQ merger), driven by superior trial outcomes (e.g., Artelo's 6.38% weight gain vs -5.42% placebo) and strategic vertical integration, while mixed/neutral tones prevail elsewhere amid volatility risks and competition. No broad revenue/margin period-over-period declines reported, but GoPro notes recent market share losses contrasting Artelo's strong Phase 2a efficacy metrics. Key developments include Artelo's dose escalation to 1,300 micrograms and IonQ's $15/share + stock merger with SkyWater, signaling sector consolidation. Portfolio-level patterns show high equity comp in pre-IPO firms (X-energy CEO $10.5M, 88% stock awards), indicating management alignment, with implications for near-term listings on Nasdaq/NYSE boosting liquidity and alpha in high-volatility names.
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from March 19, 2026.
Investment Signals(12)
- Artelo Biosciences↓(BULLISH)▲
Phase 2a CAReS trial showed mean body weight gain +6.38% vs -5.42% placebo loss, lean mass +4.23% vs -3.15%, max gain 18.5% vs 0.4% placebo; Phase 1 ART26.12 no AEs in 49 subjects
- Artelo Biosciences↓(BULLISH)▲
ART27.13 dose escalation approved to 1,300 micrograms, ART12.11 patent to 2038, FDA IND cleared July 2024
- IonQ↓(BULLISH)▲
Merger with SkyWater at $15/share cash + stock exchange ratio, no financial declines reported, Goldman Sachs fairness opinion, enhances quantum manufacturing vertical integration
- IonQ↓(BULLISH)▲
Achieved 99.99% two-qubit gate fidelity in 2025 vs prior benchmarks, Merger Agreement Jan 25, 2026
- Grayscale HYPE ETF(BULLISH)▲
S-1 for continuous offering/listing on Nasdaq (GHYP), in-kind creations/redemptions approved, Index Price via CoinDesk benchmark
- X-energy(BULLISH)▲
CEO J. Clay Sell total comp $10.5M (88% stock awards $9.2M vesting over 4 years), 2026 Equity Incentive Plan and IPO awards planned, base salary $612K
- GoPro↓(BULLISH)▲
Growth strategy via AI-driven GP3 SoC, new camera categories, 2025 AI Training program for subscriber monetization despite competition
- DentonX(BULLISH)▲
Exec transitions to experienced Lionel Pinuer as CEO/CFO Jan 1, 2026, consulting agreements with equity comp potential
- Artelo Biosciences↓(BULLISH)▲
Favorable safety in 32 enrolled patients, outperforms placebo across weight/lean mass metrics by 11.8pp and 7.38pp
- IonQ↓(BULLISH)▲
Access to SkyWater U.S. foundry for supply chain resilience, SKYT shareholders receive premium valuation
- X-energy(BULLISH)▲
Late-2025 hires with high equity grants (CFO $6.4M, COO $4.7M), vesting from Jan 2024 signals long-term conviction
- Grayscale HYPE ETF(BULLISH)▲
Non-accelerated filer/emerging growth co. status enables agile IPO path for HYPE digital assets
Risk Flags(10)
- Grayscale HYPE ETF/Volatility[HIGH RISK]▼
Highlights extreme digital asset volatility, no Investment Company Act/CEA protections, indeterminate shares
- GoPro/Competition↓[HIGH RISK]▼
Increased competition led to market share loss in recent years, GPRO closed at $0.68/share March 19, 2026
- DentonX/Governance[HIGH RISK]▼
Lacks board committees, audit expert, independent directors, code of ethics; early-stage no positive cash flows
- DentonX/Exec Turnover[MEDIUM RISK]▼
Luis Carlos Ung resigned CEO Jan 1, 2026; Irene Ying Ying Chung resigned Secretary/Treasurer
- GoPro/Resale↓[MEDIUM RISK]▼
S-1 enables resale of 120M Class A shares by selling stockholder, company receives no proceeds from convertible debentures
- Grayscale HYPE ETF/Regulatory[MEDIUM RISK]▼
Non-accelerated filer/smaller reporting co., significant investment risks emphasized in prospectus
- X-energy/Comp Structure[MEDIUM RISK]▼
No prior-year comp comparisons, heavy reliance on unvested Incentive Units over 4 years
- DentonX/Financials[HIGH RISK]▼
Exec comp low ($144K Ung, $6.9K former Sec'y), no stock options/formal agreements, development stage losses
- GoPro/Valuation↓[MEDIUM RISK]▼
Low $0.68 close reflects challenges despite growth plans, incorporates 2025 10-K showing prior declines
- IonQ/Merger↓[LOW RISK]▼
$33M Goldman fee upon closing, two-step merger with subsidiaries formed Jan 22, 2026 adds execution risk
Opportunities(10)
- Artelo Biosciences/Phase 2a Data↓(OPPORTUNITY)◆
Compelling efficacy +6.38% weight gain vs placebo in cancer anorexia, dose escalation to 1,300ug positions for Phase 2b advancement
- IonQ/SkyWater Merger↓(OPPORTUNITY)◆
Vertical integration in quantum manufacturing at $15/share + stock, premium to SKYT, enhances IONQ supply chain
- Grayscale HYPE ETF/Listing(OPPORTUNITY)◆
Nasdaq GHYP debut offers exposure to Hyperliquid HYPE assets via ETF structure, in-kind AP redemptions
- GoPro/AI Pivot↓(OPPORTUNITY)◆
GP3 SoC and AI Training program 2025 launch for monetization, potential turnaround from $0.68 low valuation
- X-energy/IPO Equity(OPPORTUNITY)◆
Planned 2026 Equity Plan + IPO awards to execs/directors, high stock comp ($10.5M CEO) aligns pre-listing
- Artelo Biosciences/Patent↓(OPPORTUNITY)◆
ART12.11 to 2038, ART26.12 Phase 1 success (no AEs, dose-dependent PK) de-risks pipeline
- IonQ/Tech Milestone↓(OPPORTUNITY)◆
99.99% fidelity milestone 2025, merger provides U.S. foundry access amid quantum demand
- DentonX/Leadership Refresh(OPPORTUNITY)◆
Pinuer/Ung team with equity consulting, early-stage entry ahead of IPO
- X-energy/Exec Alignment(OPPORTUNITY)◆
Recent hires with 4-year vesting grants from 2024/2025, nuclear energy sector tailwinds
- GoPro/Share Resale↓(OPPORTUNITY)◆
120M shares unlock liquidity post-debenture conversion, supports strategy execution
Sector Themes(6)
- Biotech Trial Outperformance(IPO ALPHA)◆
Artelo's Phase 2a metrics crush placebo (e.g., +11.8pp weight gain), Phase 1 clean safety in single filer, signals de-risked IPOs with 20%+ efficacy edges
- Quantum/Tech M&A Consolidation(STRATEGIC EDGE)◆
IonQ-SkyWater deal at premium valuation (no metric declines), vertical integration trend vs standalone IPOs like GoPro resale
- Pre-IPO Equity-Heavy Comp(MANAGEMENT SKIN)◆
X-energy/DentonX execs 80-90%+ stock awards/consulting equity (e.g., $9.2M CEO), 4-yr vesting fosters alignment across 2/6 filings
- Crypto ETF Innovation(LIQUIDITY BOOST)◆
Grayscale HYPE S-1 for Nasdaq listing mirrors spot ETF wave, neutral sentiment but continuous offering exploits volatility
- Governance Gaps in Early-Stage◆
DentonX lacks committees/independents (1/6), contrasts mature filers like GoPro/IonQ, watch for post-IPO fixes [RISK/PRICING GAP]
- Mixed Consumer Tech Recovery(TURNAROUND POTENTIAL)◆
GoPro market share loss but AI SoC pivot at $0.68 valuation outlier vs positive biotech/quantum
Watch List(8)
- Artelo Biosciences/Dose Escalation↓(NEAR-TERM CATALYST)👁
Monitor Phase 2a expansion to 1,300ug and full results post-18 evaluable patients, potential Q2 2026 update
Track closing post-Jan 25, 2026 Agreement, $33M fee trigger, SKYT delisting impacts on IONQ [Q2 2026 WATCH]
- Grayscale HYPE ETF/Nasdaq Listing(IMMINENT IPO)👁
Watch GHYP pricing/launch post-S-1 effectiveness, CoinDesk Index at 4pm NY time
Earnings incorporating 2025 10-K, GP3 SoC/AI Training progress amid $0.68 valuation [Q2 2026 UPDATE]
- X-energy/Equity Plan(POST-IPO GRANTS)👁
2026 Incentive Plan rollout and IPO awards to execs/directors upon consummation
- DentonX/IPO Governance(GOVERNANCE FIX)👁
Exec transitions complete Jan 1, 2026; audit/code of ethics additions pre-listing
- Artelo Biosciences/FDA Path↓(PIPELINE MILESTONES)👁
ART26.12 Phase 2 initiation post-June 2025 Phase 1, patent enforcement to 2038
- IonQ/Fidelity Roadmap↓(TECH CATALYST)👁
Post-merger quantum advancements building on 2025 99.99% gates
Filing Analyses(6)
20-03-2026
Grayscale HYPE ETF, a Delaware statutory trust sponsored by Grayscale Investments Sponsors, LLC, filed an S-1 registration statement on March 20, 2026, to register an indeterminate number of shares for continuous offering and listing on NASDAQ under the symbol 'GHYP'. The Trust holds HYPE digital assets from the Hyperliquid Network, issuing and redeeming shares in baskets of 10,000 to authorized participants via in-kind or cash orders. The prospectus highlights significant investment risks, extreme volatility in digital assets, and lack of protections under the Investment Company Act or CEA.
- ·Registrant classified as non-accelerated filer, smaller reporting company, and emerging growth company.
- ·Index Price based on CoinDesk Hyperliquid Benchmark Extended Rate at 4:00 p.m. New York time.
- ·NASDAQ approved in-kind creations/redemptions with authorized participants or designees.
20-03-2026
Artelo Biosciences, Inc. (ARTL) filed an S-1 registration statement on March 20, 2026, for a public offering of common stock and pre-funded warrants through placement agent Craft Capital Management LLC, with 8.0% fees and warrants equal to 8.0% of securities sold. Interim Phase 2a CAReS trial results for ART27.13 showed compelling efficacy with mean body weight gain of 6.38% (vs -5.42% placebo loss) and lean body mass increase of +4.23% (vs -3.15% placebo) in 18 evaluable cancer anorexia patients, with a favorable safety profile among 32 enrolled participants. ART26.12 Phase 1 SAD study in 49 healthy subjects reported no drug-related adverse events and dose-dependent pharmacokinetics.
- ·ART27.13 dose escalation approved up to 1,300 micrograms; max weight gain 18.5% (ART27.13) vs 0.4% (placebo); max weight loss -3.0% (ART27.13) vs -17.4% (placebo).
- ·ART12.11 composition of matter patent enforceable until December 10, 2038.
- ·ART26.12 IND cleared by FDA in July 2024; Phase 1 results announced June 2025.
- ·CAReS trial: first patient dosed April 2021; Phase 1b completed Q1 2023; Phase 2a initiated April 2023; interim announced September 3, 2025.
20-03-2026
GoPro, Inc. filed an S-1 registration statement on March 20, 2026, to enable the resale of up to 120,000,000 shares of Class A common stock by a selling stockholder upon conversion of convertible debentures issued under a Securities Purchase Agreement dated February 27, 2026; the company will receive no proceeds from these resales. The filing highlights increased competition leading to market share loss in recent years, but outlines a growth strategy centered on the next-generation AI-driven GP3 SoC, new camera categories, and the 2025-launched AI Training program for monetizing subscriber content. GoPro's common stock (GPRO) closed at $0.68 per share on March 19, 2026, reflecting a low valuation amid these challenges.
- ·GoPro is an accelerated filer under Nasdaq Global Select Market (GPRO).
- ·Principal executive offices: 3025 Clearview Way, San Mateo, California 94402.
- ·Incorporates by reference Annual Report on Form 10-K for year ended December 31, 2025.
20-03-2026
IonQ, Inc. announced a two-step merger to acquire SkyWater Technology, Inc., pursuant to a Merger Agreement dated January 25, 2026, where SkyWater shareholders will receive $15.00 per share in cash plus IonQ common stock based on the Exchange Ratio. The deal aims to provide IonQ with vertical integration in quantum computing manufacturing, access to SkyWater's U.S.-based foundry facilities, and enhanced supply chain resilience. Goldman Sachs provided a fairness opinion to SkyWater's board and will receive a $33M fee upon closing; no financial declines or flat metrics are reported in the filing.
- ·Merger Agreement dated January 25, 2026; Merger Subsidiaries formed January 22, 2026
- ·SkyWater common stock ticker: SKYT (Nasdaq); IonQ common stock ticker: IONQ (NYSE)
- ·IonQ achieved 99.99% two-qubit gate fidelity in 2025
20-03-2026
X-energy's S-1 filing discloses 2025 compensation for named executive officers, with CEO J. Clay Sell receiving total pay of $10.5M primarily from $9.2M in stock awards, while CFO Daniel Gross and COO Dragan Popovic received $6.4M and $4.7M respectively, driven by late-year hires and equity grants. The company outlines board committees including compensation, nominating and governance, plans a 2026 Equity Incentive Plan, and intends to grant IPO equity awards to executives and directors upon offering consummation. No prior-year comparisons are provided, and compensation includes standard benefits without tax gross-ups.
- ·Annual base salaries set at $612K for Sell, $550K for Gross, $450K for Popovic.
- ·Gross commenced employment November 2025; Popovic October 2025 (relocated December 2025).
- ·Incentive Units vest in equal annual installments over 4 years; Sell's June 2025 grant vests from Jan 1, 2024.
- ·Compensation committee expected: Kathleen W. Hyle (chair), Allyson Satin; Nominating/Governance: Gregory J. Goff (chair), Christopher F. Ginther, Michael J. Wallace.
- ·No compensation committee interlocks or insider participation in 2024-2025.
20-03-2026
DentonX Inc, a Wyoming-incorporated company based in Oakland, CA, filed an S-1 registration statement on March 20, 2026, ahead of a potential IPO. Key executives include Lionel Pinuer (49, CEO and CFO) and Luis Carlos Ung (45, President, Director, and Secretary), with total compensation for the year ended September 30, 2025, at $144,650 for Ung (mostly stock and other) and $6,880 for former Secretary Irene Ying Ying Chung. The company lacks formal board committees, an audit committee financial expert, independent directors, or a code of ethics, citing its early development stage and lack of positive cash flows from operations.
- ·Consulting agreements entered September 3, 2025 (Irene Ying Ying Chung and Luis Carlos Ung) and September 10, 2025 (Lionel Pinuer), compensable in cash, equity, or combination at hourly/project rates.
- ·Luis Carlos Ung resigned as CEO effective January 1, 2026; Lionel Pinuer appointed CEO and CFO on January 1, 2026; Irene Ying Ying Chung resigned as Secretary and Treasurer.
- ·No stock options granted to executives; no formal employment agreements; directors receive no compensation.
- ·No involvement of directors/officers in legal proceedings, bankruptcies, or regulatory violations in past 10 years.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 6 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)